Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)

• Published in: BMJ open diabetes research & care Vol. 9; no. 1; p. e001787
• Main Authors: Ueki, Kohjiro, Tanizawa, Yukio, Nakamura, Jiro, Yamada, Yuichiro, Inagaki, Nobuya, Watada, Hirotaka, Shimomura, Iichiro, Nishimura, Rimei, Miyoshi, Hideaki, Abiko, Atsuko, Katagiri, Hideki, Hayashi, Michio, Shimada, Akira, Naruse, Keiko, Fujimoto, Shimpei, Fujiwara, Masazumi, Shikata, Kenichi, Okada, Yosuke, Araki, Eiichi, Yamazaki, Tsutomu, Kadowaki, Takashi
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.01.2021; BMJ Publishing Group
• Subjects: Cancer therapies; Clinical care/Education/Nutrition; Clinical medicine; Diabetes; Glucagon; Heart failure; Hypoglycemia; Laboratories; Observational studies; Pancreatic cancer; Pancreatitis; Patients; Peptides; Skin diseases; Statistical analysis; Japan; diabetes mellitus; dipeptidyl peptidase 4; type 2; registries; safety
• ISSN: 2052-4897; 2052-4897
• DOI: 10.1136/bmjdrc-2020-001787

IntroductionGiven an increasing use of dipeptidyl peptidase-4 (DPP-4) inhibitors to treat patients with type 2 diabetes mellitus in the real-world setting, we conducted a prospective observational study (Japan-based Clinical Research Network for Diabetes Registry: J-BRAND Registry) to elucidate the safety and efficacy profile of long-term usage of alogliptin.Research design and methodsWe registered 5969 patients from April 2012 through September 2014, who started receiving alogliptin (group A) or other classes of oral hypoglycemic agents (OHAs; group B), and were followed for 3 years at 239 sites nationwide. Safety was the primary outcome. Symptomatic hypoglycemia, pancreatitis, skin disorders of non-extrinsic origin, severe infections, and cancer were collected as major adverse events (AEs). Efficacy assessment was the secondary outcome and included changes in hemoglobin A1c (HbA1c), fasting blood glucose, fasting insulin and urinary albumin.ResultsOf the registered, 5150 (group A: 3395 and group B: 1755) and 5096 (3358 and 1738) were included for safety and efficacy analysis, respectively. Group A patients mostly (>90%) continued to use alogliptin. In group B, biguanides were the primary agents, while DPP-4 inhibitors were added in up to ~36% of patients. The overall incidence of AEs was similar between the two groups (42.7% vs 42.2%). Kaplan-Meier analysis revealed the incidence of cancer was significantly higher in group A than in group B (7.4% vs 4.8%, p=0.040), while no significant incidence difference was observed in the individual cancer. Multivariate Cox regression analysis revealed that the imbalanced patient distribution (more elderly patients in group A than in group B), but not alogliptin usage per se, contributed to cancer development. The incidence of other major AE categories was with no between-group difference. Between-group difference was not detected, either, in the incidence of microvascular and macrovascular complications. HbA1c and fasting glucose decreased significantly at the 0.5-year visit and nearly plateaued thereafter in both groups.ConclusionsAlogliptin as a representative of DPP-4 inhibitors was safe and durably efficacious when used alone or with other OHAs for patients with type 2 diabetes in the real world setting.